Autolus Therapeutics Ltd (AUTL) — Cash Flow-to-Debt Ratio
Autolus Therapeutics Ltd (AUTL) has a Cash Flow-to-Debt Ratio of -0.16x as of December 2025, meaning its operating cash flow of $-67.32 Million could theoretically repay 0% of its total liabilities ($410.94 Million) in one year. See Autolus Therapeutics Ltd (AUTL) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Autolus Therapeutics Ltd Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Autolus Therapeutics Ltd across 12 annual periods. Also explore net asset momentum of Autolus Therapeutics Ltd to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Autolus Therapeutics Ltd (2015–2025)
Year-by-year debt coverage analysis for Autolus Therapeutics Ltd. For market capitalisation and broader financial context, see Autolus Therapeutics Ltd stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.69x | $-283.57 Million | $410.94 Million | ▼ -18.9% |
| 2024 | -0.58x | $-206.27 Million | $355.40 Million | ▼ -5.2% |
| 2023 | -0.55x | $-145.59 Million | $263.91 Million | ▲ +5.9% |
| 2022 | -0.59x | $-112.31 Million | $191.60 Million | ▲ +54.1% |
| 2021 | -1.28x | $-117.86 Million | $92.24 Million | ▲ +8.6% |
| 2020 | -1.40x | $-117.76 Million | $84.20 Million | ▲ +32.9% |
| 2019 | -2.08x | $-101.48 Million | $48.69 Million | ▼ -0.9% |
| 2018 | -2.06x | $-25.85 Million | $12.52 Million | ▲ +0.0% |
| 2018 | -2.06x | $-25.85 Million | $12.52 Million | ▲ +23.5% |
| 2017 | -2.70x | $-16.36 Million | $6.06 Million | ▲ +4.3% |
| 2016 | -2.82x | $-9.85 Million | $3.49 Million | ▼ -65.2% |
| 2015 | -1.71x | $-3.33 Million | $1.95 Million | — |